The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases
Open accessAbstract
Myelin oligodendrocyte glycoprotein (MOG), a member of the immunoglobulin (Ig) superfamily, is a myelin protein solely expressed at the outermost surface of myelin sheaths and oligodendrocyte membranes. This makes MOG a potential target of cellular and humoral immune responses in inflammatory demyelinating diseases. Due to its late postnatal developmental expression, MOG is an important marker for oligodendrocyte maturation. Discovered about 30 years ago, it is one of the best-studied autoantigens for experimental autoimmune models for multiple sclerosis (MS). Human studies, however, have yielded controversial results on the role of MOG, especially MOG antibodies, as a biomarker in MS. But with improved detection methods using different expression systems to detect antibodies in patients´ samples, this is meanwhile no longer the case. Using cell-based assays with recombinant full-length, conformationally intact MOG, several recent studies have revealed that MOG antibodies can be found in a subset of predominantly pediatric patients with acute disseminated encephalomyelitis (ADEM), aquaporin-4 (AQP4) seronegative neuromyelitis optica spectrum disorders (NMOSD), monophasic or recurrent isolated optic neuritis or transverse myelitis, in atypical MS and in N-methyl-D-aspartate receptor (NMDAR)-encephalitis with overlapping demyelinating syndromes. Whereas MOG antibodies are only transiently observed in monophasic diseases such as ADEM and their decline is associated with a favorable outcome, they are persistent in multiphasic ADEM, NMOSD or recurrent optic neuritis or myelitis. Due to distinct clinical features within these diseases it is controversially disputed to classify MOG antibody positive cases as a new disease entity. Neuropathologically, the presence of MOG antibodies is characterized by MS-typical demyelination and oligodendrocyte pathology associated with antibodies and complement. However, it remains unclear whether MOG antibodies are a mere inflammatory bystander effect or truly pathogenetic. This article provides deeper insight into recent developments, the clinical relevance of MOG antibodies and their role in the immunpathogenesis of inflammatory demyelinating disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
B cells regulate autoimmunity by provision of IL-10
Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D., & Anderton, S. M. (2002) · Nature Immunology · doi:10.1038/ni833 · Cited by 1,647
Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination
Berer, K., Mues, M., Koutrolos, M., Rasbi, Z. A., Boziki, M., Johner, C., Wekerle, H., & Krishnamoorthy, G. (2011) · Nature · doi:10.1038/nature10554 · Cited by 1,251
Insulin antibodies in insulin-dependent diabetics before insulin treatment
Palmer, J. P., Asplin, C. M., Clemons, P., Lyen, K., Tatpati, O., Raghu, P. K., & Paquette, T. L. (1983) · Science · doi:10.1126/science.6362005 · Cited by 1,078
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
Sato, D. K., Callegaro, D., Lana-Peixoto, M. A., Waters, P. J., Jorge, F. M. D. H., Takahashi, T., Nakashima, I., Apostolos-Pereira, S. L., Talim, N., Simm, R. F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000101 · Cited by 850
Kitley, J., Waters, P., Woodhall, M., Leite, M. I., Murchison, A., George, J., Küker, W., Chandratre, S., Vincent, A., & Palace, J. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5857 · Cited by 597
Multiple sclerosis: experimental models and reality
Lassmann, H., & Bradl, M. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1631-4 · Cited by 525
Self-citationBettelli, E., Baeten, D., Jäger, A., Sobel, R. A., & Kuchroo, V. K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28334 · Cited by 336 · cited 3×
“These models were based on the transgenic expression in mice of MOG-specific T cell receptors, either alone (71, 78) or in combination with MOG-specific B cell receptors (74, 97) and gave striking results: The overexpression of MOG-specific T cell receptors in transgenic C57/BL6 (71) or SJL (78) mice lead to spontaneo…”
BackgroundResultMyelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children
Hacohen, Y., Absoud, M., Deiva, K., Hemingway, C., Nytrova, P., Woodhall, M., Palace, J., Wassmer, E., Tardieu, M., Vincent, A., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000081 · Cited by 230
Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis
Spadaro, M., Gerdes, L. A., Krumbholz, M., Ertl-Wagner, B., Thaler, F. S., Schuh, E., Metz, I., Blaschek, A., Dick, A., Brück, W., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000257 · Cited by 206
Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis
Rostasy, K., Mader, S., Schanda, K., Huppke, P., Gärtner, J., Kraus, V., Karenfort, M., Tibussek, D., Blaschek, A., Bajer-Kornek, B., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.2956 · Cited by 182
Self-citation
Cited by
Myelin oligodendrocyte glycoprotein antibodies in neurological disease
Reindl, M., & Waters, P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0112-x · Cited by 626
Self-citationHöftberger, R., Guo, Y., Flanagan, E. P., Lopez-Chiriboga, A. S., Endmayr, V., Hochmeister, S., Joldic, D., Pittock, S. J., Tillema, J. M., Gorman, M., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02132-y · Cited by 369
Self-citationMyelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study
Takai, Y., Misu, T., Kaneko, K., Chihara, N., Narikawa, K., Tsuchida, S., Nishida, H., Komori, T., Seki, M., Komatsu, T., et al. (2020) · Brain · doi:10.1093/brain/awaa102 · Cited by 299
Self-citationKotsiliti, E., Leone, V., Schuehle, S., Govaere, O., Li, H., Wolf, M. J., Horvatic, H., Bierwirth, S., Hundertmark, J., Inverso, D., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.037 · Cited by 108
Extracellular Vesicles of Alzheimer’s Disease Patients as a Biomarker for Disease Progression
Aharon, A., Spector, P., Ahmad, R. S., Horrany, N., Sabbach, A., Brenner, B., & Aharon-Peretz, J. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02013-1 · Cited by 90
Metadata
- Authors
- Peschl, P., Bradl, M., Höftberger, R., Berger, T., & Reindl, M.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2017-05-08
- Volume
- 8
- Pages
- 529-529
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2612531229
- Cited by
- 244
- References
- 11
- FWCI
- 17.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases. https://app.cochat.ai/papers/10.3389/fimmu.2017.00529
- The paper
- Peschl, P., Bradl, M., Höftberger, R., Berger, T., & Reindl, M. (2017). Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2017.00529
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.